Literature DB >> 8938566

Determination of interferon-alpha-producing capacity in whole blood cultures from patients with various diseases and from healthy persons.

K Uno1, K Nakano, N Maruo, H Onodera, H Mata, I Kurosu, K Akatani, N Ikegami, A Kishi, Y Yasuda, K Tanaka, J Setoguchi, M Kondo, S Muramatsu, T Kishida.   

Abstract

To assess the clinical value of determination of the interferon (IFN)-producing capacity of patients, IFN production induced by Sendai virus (HVJ) in vitro was measured in cell cultures of whole blood from patients with various diseases. IFN production in patients with lung cancer, myelodysplastic syndromes, noninsulin-dependent diabetes mellitus, pulmonary tuberculosis, and asymptomatic HIV-1 infection was lower than that in healthy persons. Furthermore, periodic measurements of IFN production revealed decreasing IFN producing capacities in patients with lung cancer with progression of the tumor stage. However, increased IFN-producing capacities were observed in patients with tuberculosis after standard therapy. Further experiments showed that the main type of IFN induced in whole blood cultures was IFN-alpha, and decreased IFN production in patients did not result from a decreased number of leukocytes but rather from an impairment of cellular IFN production. The evaluation of IFN production in whole blood cell cultures may be a feasible method of assessing the impaired immune status.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8938566     DOI: 10.1089/jir.1996.16.911

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  7 in total

1.  Immunomodulatory effects of cyclosporin A on human peripheral blood dendritic cell subsets.

Authors:  Kenichirou Tajima; Ryuichi Amakawa; Tomoki Ito; Michihiko Miyaji; Masashi Takebayashi; Shirou Fukuhara
Journal:  Immunology       Date:  2003-03       Impact factor: 7.397

2.  Impairment of IFN-alpha production capacity in patients with hepatitis C virus and the risk of the development of hepatocellular carcinoma.

Authors:  Kazuko Uno; Yoshiki Suginoshita; Kazuhiro Kakimi; Fuminori Moriyasu; Mayumi Hirosaki; Taro Shirakawa; Tsunataro Kishida
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

3.  Adoptive cellular therapy enhances the helper T cell response and reduces the number of regulatory T cells.

Authors:  Takeshi Ishikawa; Satoshi Kokura; Naoyuki Sakamoto; Tsuguhiro Matsumoto; Jun Funaki; Satoko Adachi; Tetsuya Okayama; Kazuhiko Uchiyama; Osamu Handa; Tomohisa Takagi; Nobuaki Yagi; Takashi Ando; Kazuko Uno; Yuji Naito; Toshikazu Yoshikawa
Journal:  Exp Ther Med       Date:  2011-05-12       Impact factor: 2.447

4.  Prostaglandin E2 is a negative regulator on human plasmacytoid dendritic cells.

Authors:  Yonsu Son; Tomoki Ito; Yoshio Ozaki; Tsutomu Tanijiri; Takashi Yokoi; Kengo Nakamura; Masashi Takebayashi; Ryuichi Amakawa; Shirou Fukuhara
Journal:  Immunology       Date:  2006-06-06       Impact factor: 7.397

5.  Association between IFNA genotype and the risk of sarcoidosis.

Authors:  Mitsuteru Akahoshi; Mami Ishihara; Natascha Remus; Kazuko Uno; Katsuhisa Miyake; Tomomitsu Hirota; Kazuko Nakashima; Akira Matsuda; Mizuo Kanda; Tadao Enomoto; Shigeaki Ohno; Hitoshi Nakashima; Jean-Laurent Casanova; Julian M Hopkin; Mayumi Tamari; Xiao-Quan Mao; Taro Shirakawa
Journal:  Hum Genet       Date:  2004-03-05       Impact factor: 4.132

6.  IFN production ability and healthy ageing: mixed model analysis of a 24 year longitudinal study in Japan.

Authors:  Kazuko Uno; Katsumi Yagi; Masayo Yoshimori; Mari Tanigawa; Toshikazu Yoshikawa; Setsuya Fujita
Journal:  BMJ Open       Date:  2013-01-11       Impact factor: 2.692

7.  Phase I clinical trial of fibronectin CH296-stimulated T cell therapy in patients with advanced cancer.

Authors:  Takeshi Ishikawa; Satoshi Kokura; Tatsuji Enoki; Naoyuki Sakamoto; Tetsuya Okayama; Mitsuko Ideno; Junichi Mineno; Kazuko Uno; Naohisa Yoshida; Kazuhiro Kamada; Kazuhiro Katada; Kazuhiko Uchiyama; Osamu Handa; Tomohisa Takagi; Hideyuki Konishi; Nobuaki Yagi; Yuji Naito; Yoshito Itoh; Toshikazu Yoshikawa
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.